A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)

Onkologie

Volumn 31, Issue 4, 2008, Pages 185-189

  Görn, Michael ^a,c   Habermann, Christian R ^a   Anige, Manuela ^a   Thöm, Ina ^a   Schuch, Gunter ^a   Andritzky, Birte ^a   Brandl, Stefan ^a   Burkholder, Iris ^b   Edler, Lutz ^b   Hossfeld, Dieter Kurt ^a   Bokemeyer, Carsten ^a   Laack, Eckart ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Innovation Onkologie Research and Consulting GmbH   (Germany)

Author keywords

Metronomic second line chemotherapy; Non small cell lung cancer; Pilot study

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; SEROTONIN 3 ANTAGONIST; TROFOSFAMIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PILOT STUDY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PILOT PROJECTS; SURVIVAL ANALYSIS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 43949135185     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000118626     Document Type: Article

References (23)

1. Bunn PA Jr, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:1087-1100.
2. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
3. Jassem J: Chemotherapy of advanced non-small cell lung cancer. Ann Oncol 1997;10:77-82.
4. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J Clin Invest 2000;105:10045-10047.
5. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
6. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF-receptor-2 antibody induces sustained tumour regression without overt toxicity. J Clin Invest 2000;105:R15-24.
7. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
8. Horvath V, Hartlapp JH, Hegewisch-Becker S: Oral trofosfamide in elderly and/or heavily pretreated patients with metastatic lung cancer. Onkologie 2000;23:341-344.
9. Simon R: Design, analysis, and reporting of cancer clinical trials; in Peace KE (ed): Biopharmaceutical Statistics for Drug Development. New York, M. Dekker, 1988.
10. Laack E, Dierlamm T, Knuffmann C, Popp J, Schmied B, Durk H, Wacker-Backhaus G, Zeller W, Verpoort K, Fiedler W, Hossfeld DK: Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer 2002;36:303-307.
11. Seto T, Takezako Y, Nakamura H, Takeda K, Inoue F, Semba H, Eguchi K: Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study. Int J Clin Oncol 2004;9:378-382.
12. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH: Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small cell lung cancer. J Clin Oncol 2006;24:5025-5033.
13. Grossi F, Fasola G, Rossetto C, Spizzo R, Meduri S, Sibau A, Vigevani E, Tumolo S, Adami G, Sacco C, Recchia L, Rizzato S, Ceschia T, Belvedere O: Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer 2006;52:89-92.
14. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG: Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol 2001;28:4-9.
15. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M: Phase III study of second-line chemotherapy for advanced non-small cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:8389-8395.
16. Bria E, Cuppone F, Ciccarese M, Nistico C, Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F, Giannarelli D: Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006;32:583-587.
17. Klink T, Bela C, Stoelting S, Peters So, Broll R, Wagner T: Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. J Cancer Res Clin Oncol 2006;132:643-652.
18. Al-Batran SE, Atmaca A, Bert F, Jager D, Frisch C, Neumann A, Orth J, Knuth A, Jager E: Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer. Onkologie 2004;27:543-548.
19. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS: Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-3391.
20. Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS: Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005;14:466-479.
21. Bartsch V: Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma (article in German). Onkologie 2006;29(suppl 1):1-28.
22. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
23. Maraveyas A, Lam T, Hetherington JW, Greenman J: Can a rational design for metronomic chemotherapy dosing be devised? Br J Cancer 2005;92:1588-1590.